| November 1, 2025 |
MLTX |
An Open-label Study in Healthy Adults to Evaluate the Relative Bioequivalence of a Single-dose Administration of Sonelokimab Either by a Prefilled Syringe or an Autoinjector |
Trial Milestone |
Phase 1 |
| November 2, 2025 |
IMVT |
Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease |
Trial Milestone |
Phase 3 |
| November 3, 2025 |
AZN |
Results filed (6-K) |
Earnings |
— |
| November 3, 2025 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| November 3, 2025 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| November 3, 2025 |
BMY |
8-K filed: Other event |
Filing |
— |
| November 3, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| November 3, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| November 3, 2025 |
SNY |
6-K filed: Foreign issuer report |
Filing |
— |
| November 3, 2025 |
BNTX |
6-K filed: Foreign issuer report |
Filing |
— |
| November 3, 2025 |
BNTX |
6-K filed: Foreign issuer report |
Filing |
— |
| November 3, 2025 |
IONS |
8-K/A filed: Material agreement |
Corporate |
— |
| November 3, 2025 |
AXSM |
Quarterly results filed (8-K) |
Earnings |
— |
| November 3, 2025 |
NUVB |
Quarterly results filed (8-K) |
Earnings |
— |
| November 3, 2025 |
XENE |
Quarterly results filed (8-K) |
Earnings |
— |
| November 3, 2025 |
TGTX |
Quarterly results filed (8-K) |
Earnings |
— |
| November 3, 2025 |
KPTI |
Quarterly results filed (8-K) |
Earnings |
— |
| November 3, 2025 |
ACAD |
8-K filed: Leadership change |
Corporate |
— |
| November 3, 2025 |
LQDA |
Quarterly results filed (8-K) |
Earnings |
— |
| November 3, 2025 |
SRPT |
Quarterly results filed (8-K) |
Earnings |
— |
| November 3, 2025 |
CANF |
6-K filed: Foreign issuer report |
Filing |
— |
| November 3, 2025 |
DNTH |
8-K filed: Other event |
Filing |
— |
| November 3, 2025 |
RCUS |
8-K filed: Other event |
Filing |
— |
| November 3, 2025 |
KRYS |
Quarterly results filed (8-K) |
Earnings |
— |
| November 3, 2025 |
COGT |
Quarterly results filed (8-K) |
Earnings |
— |
| November 3, 2025 |
AWHL |
8-K/A filed: Material agreement |
Corporate |
— |
| November 3, 2025 |
SNDX |
Quarterly results filed (8-K) |
Earnings |
— |
| November 3, 2025 |
VOR |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| November 3, 2025 |
CRBP |
8-K filed: Material agreement, Reg FD disclosure |
Corporate |
— |
| November 3, 2025 |
QURE |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| November 3, 2025 |
SLDB |
Quarterly results filed (8-K) |
Earnings |
— |
| November 3, 2025 |
LYEL |
8-K filed: Leadership change |
Corporate |
— |
| November 3, 2025 |
PRQR |
6-K filed: Foreign issuer report |
Filing |
— |
| November 3, 2025 |
KYTX |
8-K filed: Material agreement, Reg FD disclosure |
Corporate |
— |
| November 3, 2025 |
OMER |
Study of the Safety and Efficacy of OMS906 in Patients With Paroxysmal Nocturnal Hemoglobinuria |
Trial Milestone |
Phase 1 |
| November 3, 2025 |
CATX |
8-K filed: Leadership change |
Corporate |
— |
| November 3, 2025 |
HALO |
Quarterly results filed (8-K) |
Earnings |
— |
| November 3, 2025 |
RADX |
6-K filed: Foreign issuer report |
Filing |
— |
| November 3, 2025 |
BCRX |
Quarterly results filed (8-K) |
Earnings |
— |
| November 3, 2025 |
LKFT |
6-K filed: Foreign issuer report |
Filing |
— |
| November 3, 2025 |
VRTX |
Quarterly results filed (8-K) |
Earnings |
— |
| November 3, 2025 |
OTLK |
8-K filed: Other event |
Filing |
— |
| November 3, 2025 |
TCRX |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| November 3, 2025 |
HURA |
8-K filed: Other event |
Filing |
— |
| November 3, 2025 |
CLLS |
6-K filed: Foreign issuer report |
Filing |
— |
| November 3, 2025 |
CGEM |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| November 3, 2025 |
BDTX |
Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations |
Trial Milestone |
Phase 1/Phase 2 |
| November 4, 2025 |
PFE |
Quarterly results filed (8-K) |
Earnings |
— |
| November 4, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| November 4, 2025 |
AMGN |
Quarterly results filed (8-K) |
Earnings |
— |
| November 4, 2025 |
NVO |
A Study to See How Safe a New Medicine (NNC0705-0001) is in Healthy People |
Trial Milestone |
Phase 1 |
| November 4, 2025 |
EXEL |
Quarterly results filed (8-K) |
Earnings |
— |
| November 4, 2025 |
AAPG |
6-K filed: Foreign issuer report |
Filing |
— |
| November 4, 2025 |
RARE |
Quarterly results filed (8-K) |
Earnings |
— |
| November 4, 2025 |
MRNA |
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age |
Trial Milestone |
Phase 3 |
| November 4, 2025 |
MIRM |
Quarterly results filed (8-K) |
Earnings |
— |
| November 4, 2025 |
TSHA |
Quarterly results filed (8-K) |
Earnings |
— |
| November 4, 2025 |
VSTM |
Quarterly results filed (8-K) |
Earnings |
— |
| November 4, 2025 |
OCUL |
Quarterly results filed (8-K) |
Earnings |
— |
| November 4, 2025 |
IDYA |
Quarterly results filed (8-K) |
Earnings |
— |
| November 4, 2025 |
GRFS |
6-K filed: Foreign issuer report |
Filing |
— |
| November 4, 2025 |
MDGL |
Quarterly results filed (8-K) |
Earnings |
— |
| November 4, 2025 |
PCVX |
Quarterly results filed (8-K) |
Earnings |
— |
| November 4, 2025 |
RYTM |
Quarterly results filed (8-K) |
Earnings |
— |
| November 4, 2025 |
CORT |
Quarterly results filed (8-K) |
Earnings |
— |
| November 4, 2025 |
SUPN |
Quarterly results filed (8-K) |
Earnings |
— |
| November 4, 2025 |
VTGN |
8-K filed: Reg FD disclosure |
Filing |
— |
| November 4, 2025 |
CMPS |
Quarterly results filed (8-K) |
Earnings |
— |
| November 4, 2025 |
DCTH |
Quarterly results filed (8-K) |
Earnings |
— |
| November 4, 2025 |
RLMD |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| November 4, 2025 |
TNGX |
Quarterly results filed (8-K) |
Earnings |
— |
| November 4, 2025 |
PHAT |
8-K filed: Other event |
Filing |
— |
| November 4, 2025 |
BEAM |
Quarterly results filed (8-K) |
Earnings |
— |
| November 4, 2025 |
STOK |
Quarterly results filed (8-K) |
Earnings |
— |
| November 4, 2025 |
CRVS |
Quarterly results filed (8-K) |
Earnings |
— |
| November 4, 2025 |
KURA |
Quarterly results filed (8-K) |
Earnings |
— |
| November 4, 2025 |
SYRE |
Quarterly results filed (8-K) |
Earnings |
— |
| November 4, 2025 |
ONCY |
6-K filed: Foreign issuer report |
Filing |
— |
| November 4, 2025 |
TTRX |
8-K filed: Reg FD disclosure |
Filing |
— |
| November 4, 2025 |
VALN |
6-K filed: Foreign issuer report |
Filing |
— |
| November 4, 2025 |
RADX |
6-K filed: Foreign issuer report |
Filing |
— |
| November 4, 2025 |
KYMR |
Quarterly results filed (8-K) |
Earnings |
— |
| November 4, 2025 |
LPCN |
8-K filed: Other event |
Filing |
— |
| November 4, 2025 |
HURA |
8-K filed: Material agreement |
Corporate |
— |
| November 4, 2025 |
ACIU |
6-K filed: Foreign issuer report |
Filing |
— |
| November 4, 2025 |
GNPX |
8-K filed: Other event |
Filing |
— |
| November 4, 2025 |
RIGL |
Quarterly results filed (8-K) |
Earnings |
— |
| November 5, 2025 |
NVS |
6-K filed: Foreign issuer report |
Filing |
— |
| November 5, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| November 5, 2025 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| November 5, 2025 |
SVA |
6-K filed: Foreign issuer report |
Filing |
— |
| November 5, 2025 |
NBIX |
Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease |
Trial Milestone |
Phase 3 |
| November 5, 2025 |
JAZZ |
Quarterly results filed (8-K) |
Earnings |
— |
| November 5, 2025 |
RVMD |
Quarterly results filed (8-K) |
Earnings |
— |
| November 5, 2025 |
IBRX |
Quarterly results filed (8-K) |
Earnings |
— |
| November 5, 2025 |
PRAX |
Quarterly results filed (8-K) |
Earnings |
— |
| November 5, 2025 |
EYPT |
Quarterly results filed (8-K) |
Earnings |
— |
| November 5, 2025 |
ACAD |
Quarterly results filed (8-K) |
Earnings |
— |
| November 5, 2025 |
OCGN |
Quarterly results filed (8-K) |
Earnings |
— |
| November 5, 2025 |
CYTK |
Quarterly results filed (8-K) |
Earnings |
— |
| November 5, 2025 |
TEVA |
Quarterly results filed (8-K) |
Earnings |
— |
| November 5, 2025 |
VIR |
Quarterly results filed (8-K) |
Earnings |
— |
| November 5, 2025 |
VTRS |
A Trial to Compare What the Body Does to Selatogrel and the Effect of Selatogrel in Japanese and Caucasian Healthy Participants |
Trial Milestone |
Phase 1 |
| November 5, 2025 |
MLTX |
8-K filed: Material agreement |
Corporate |
— |
| November 5, 2025 |
MLTX |
Quarterly results filed (8-K) |
Earnings |
— |
| November 5, 2025 |
DNTH |
Quarterly results filed (8-K) |
Earnings |
— |
| November 5, 2025 |
PVLA |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| November 5, 2025 |
DYN |
Quarterly results filed (8-K) |
Earnings |
— |
| November 5, 2025 |
GERN |
Quarterly results filed (8-K) |
Earnings |
— |
| November 5, 2025 |
MESO |
6-K filed: Foreign issuer report |
Filing |
— |
| November 5, 2025 |
VERA |
Quarterly results filed (8-K) |
Earnings |
— |
| November 5, 2025 |
RLMD |
8-K filed: Material agreement, Reg FD disclosure |
Corporate |
— |
| November 5, 2025 |
TYRA |
Quarterly results filed (8-K) |
Earnings |
— |
| November 5, 2025 |
LRMR |
Quarterly results filed (8-K) |
Earnings |
— |
| November 5, 2025 |
LXEO |
Quarterly results filed (8-K) |
Earnings |
— |
| November 5, 2025 |
RXRX |
Quarterly results filed (8-K) |
Earnings |
— |
| November 5, 2025 |
HALO |
8-K filed: Material agreement, Other event |
Corporate |
— |
| November 5, 2025 |
BTMD |
Quarterly results filed (8-K) |
Earnings |
— |
| November 5, 2025 |
XFOR |
Quarterly results filed (8-K) |
Earnings |
— |
| November 5, 2025 |
TPST |
Quarterly results filed (8-K) |
Earnings |
— |
| November 5, 2025 |
CRDL |
6-K filed: Foreign issuer report |
Filing |
— |
| November 5, 2025 |
GOSS |
Quarterly results filed (8-K) |
Earnings |
— |
| November 5, 2025 |
IMNM |
A Varegacestat Hepatic Impairment Study |
Trial Milestone |
Phase 1 |
| November 5, 2025 |
MNKD |
Quarterly results filed (8-K) |
Earnings |
— |
| November 5, 2025 |
XNCR |
Quarterly results filed (8-K) |
Earnings |
— |
| November 6, 2025 |
AZN |
Results filed (6-K) |
Earnings |
— |
| November 6, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| November 6, 2025 |
ONC |
Quarterly results filed (8-K) |
Earnings |
— |
| November 6, 2025 |
MRNA |
Quarterly results filed (8-K) |
Earnings |
— |
| November 6, 2025 |
FDMT |
Quarterly results filed (8-K) |
Earnings |
— |
| November 6, 2025 |
DFTX |
Quarterly results filed (8-K) |
Earnings |
— |
| November 6, 2025 |
QNRX |
Quarterly results filed (8-K) |
Earnings |
— |
| November 6, 2025 |
EYPT |
8-K filed: Other event |
Filing |
— |
| November 6, 2025 |
NTLA |
Quarterly results filed (8-K) |
Earnings |
— |
| November 6, 2025 |
IOVA |
Quarterly results filed (8-K) |
Earnings |
— |
| November 6, 2025 |
PHAR |
6-K filed: Foreign issuer report |
Filing |
— |
| November 6, 2025 |
REPL |
Quarterly results filed (8-K) |
Earnings |
— |
| November 6, 2025 |
VTRS |
Quarterly results filed (8-K) |
Earnings |
— |
| November 6, 2025 |
RGNX |
Quarterly results filed (8-K) |
Earnings |
— |
| November 6, 2025 |
URGN |
Quarterly results filed (8-K) |
Earnings |
— |
| November 6, 2025 |
RAPP |
Quarterly results filed (8-K) |
Earnings |
— |
| November 6, 2025 |
IMCR |
Quarterly results filed (8-K) |
Earnings |
— |
| November 6, 2025 |
LNTH |
Quarterly results filed (8-K) |
Earnings |
— |
| November 6, 2025 |
DNLI |
Quarterly results filed (8-K) |
Earnings |
— |
| November 6, 2025 |
NKTR |
Quarterly results filed (8-K) |
Earnings |
— |
| November 6, 2025 |
LBRX |
Quarterly results filed (8-K) |
Earnings |
— |
| November 6, 2025 |
RNAC |
Quarterly results filed (8-K) |
Earnings |
— |
| November 6, 2025 |
IRD |
8-K filed: Material agreement, Other event |
Corporate |
— |
| November 6, 2025 |
IRD |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| November 6, 2025 |
PTGX |
Quarterly results filed (8-K) |
Earnings |
— |
| November 6, 2025 |
IVVD |
Quarterly results filed (8-K) |
Earnings |
— |
| November 6, 2025 |
VCEL |
Quarterly results filed (8-K) |
Earnings |
— |
| November 6, 2025 |
VERA |
8-K filed: Other event |
Filing |
— |
| November 6, 2025 |
AMLX |
Quarterly results filed (8-K) |
Earnings |
— |
| November 6, 2025 |
EWTX |
Quarterly results filed (8-K) |
Earnings |
— |
| November 6, 2025 |
MBX |
Quarterly results filed (8-K) |
Earnings |
— |
| November 6, 2025 |
PRQR |
6-K filed: Foreign issuer report |
Filing |
— |
| November 6, 2025 |
PBH |
Quarterly results filed (8-K) |
Earnings |
— |
| November 6, 2025 |
RLAY |
Quarterly results filed (8-K) |
Earnings |
— |
| November 6, 2025 |
VTVT |
Quarterly results filed (8-K) |
Earnings |
— |
| November 6, 2025 |
PCRX |
Quarterly results filed (8-K) |
Earnings |
— |
| November 6, 2025 |
ALT |
8-K filed: Material agreement |
Corporate |
— |
| November 6, 2025 |
ALT |
Quarterly results filed (8-K) |
Earnings |
— |
| November 6, 2025 |
NGNE |
8-K filed: Reg FD disclosure |
Filing |
— |
| November 6, 2025 |
KYNB |
8-K filed: Other event |
Filing |
— |
| November 6, 2025 |
LONA |
Quarterly results filed (8-K) |
Earnings |
— |
| November 6, 2025 |
INTS |
Quarterly results filed (8-K) |
Earnings |
— |
| November 6, 2025 |
CLYM |
Quarterly results filed (8-K) |
Earnings |
— |
| November 6, 2025 |
PBYI |
Quarterly results filed (8-K) |
Earnings |
— |
| November 6, 2025 |
CATX |
8-K filed: Other event |
Filing |
— |
| November 6, 2025 |
NTHI |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| November 6, 2025 |
BCLI |
8-K filed: Material agreement |
Corporate |
— |
| November 6, 2025 |
IRON |
Quarterly results filed (8-K) |
Earnings |
— |
| November 6, 2025 |
LXRX |
8-K filed: Other event |
Filing |
— |
| November 6, 2025 |
LXRX |
Quarterly results filed (8-K) |
Earnings |
— |
| November 6, 2025 |
LKFT |
6-K filed: Foreign issuer report |
Filing |
— |
| November 6, 2025 |
TRDA |
Quarterly results filed (8-K) |
Earnings |
— |
| November 6, 2025 |
ACHV |
Quarterly results filed (8-K) |
Earnings |
— |
| November 6, 2025 |
LPCN |
Quarterly results filed (8-K) |
Earnings |
— |
| November 6, 2025 |
IMNM |
Quarterly results filed (8-K) |
Earnings |
— |
| November 6, 2025 |
TMCI |
Quarterly results filed (8-K) |
Earnings |
— |
| November 6, 2025 |
CERS |
Quarterly results filed (8-K) |
Earnings |
— |
| November 6, 2025 |
CRIS |
Quarterly results filed (8-K) |
Earnings |
— |
| November 6, 2025 |
MAZE |
Quarterly results filed (8-K) |
Earnings |
— |
| November 6, 2025 |
BIOA |
Quarterly results filed (8-K) |
Earnings |
— |
| November 6, 2025 |
CGEM |
Quarterly results filed (8-K) |
Earnings |
— |
| November 6, 2025 |
ALLO |
Quarterly results filed (8-K) |
Earnings |
— |
| November 6, 2025 |
BDTX |
Quarterly results filed (8-K) |
Earnings |
— |
| November 7, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| November 7, 2025 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| November 7, 2025 |
EXEL |
8-K filed: Leadership change, Other event |
Corporate |
— |
| November 7, 2025 |
INBS |
Quarterly results filed (8-K) |
Earnings |
— |
| November 7, 2025 |
SMMT |
8-K filed: Other event |
Filing |
— |
| November 7, 2025 |
FDMT |
8-K filed: Other event |
Filing |
— |
| November 7, 2025 |
RYTM |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| November 7, 2025 |
ALXO |
Quarterly results filed (8-K) |
Earnings |
— |
| November 7, 2025 |
ELDN |
Quarterly results filed (8-K) |
Earnings |
— |
| November 7, 2025 |
MAIA |
8-K filed: Other event |
Filing |
— |
| November 7, 2025 |
BFRI |
8-K filed: Material agreement, Acquisition completed, Reg FD disclosure |
Corporate |
— |
| November 7, 2025 |
HALO |
8-K filed: Other event |
Filing |
— |
| November 7, 2025 |
OGN |
8-K filed: Leadership change |
Corporate |
— |
| November 7, 2025 |
CLLS |
6-K filed: Foreign issuer report |
Filing |
— |
| November 7, 2025 |
KPRX |
Quarterly results filed (8-K) |
Earnings |
— |
| November 7, 2025 |
DRUG |
6-K filed: Foreign issuer report |
Filing |
— |
| November 7, 2025 |
DRUG |
6-K filed: Foreign issuer report |
Filing |
— |
| November 8, 2025 |
LLY |
A Study of Multiple Olomorasib (LY3537982) Capsules in Healthy Participants |
Trial Milestone |
Phase 1 |
| November 10, 2025 |
AZN |
6-K filed: Corporate announcement |
Corporate |
— |
| November 10, 2025 |
BMY |
8-K filed: Other event |
Filing |
— |
| November 10, 2025 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| November 10, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| November 10, 2025 |
IONS |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| November 10, 2025 |
FDMT |
Quarterly results filed (8-K) |
Earnings |
— |
| November 10, 2025 |
CLDX |
Quarterly results filed (8-K) |
Earnings |
— |
| November 10, 2025 |
NTLA |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| November 10, 2025 |
IMVT |
Quarterly results filed (8-K) |
Earnings |
— |
| November 10, 2025 |
CABA |
Quarterly results filed (8-K) |
Earnings |
— |
| November 10, 2025 |
ANNX |
Quarterly results filed (8-K) |
Earnings |
— |
| November 10, 2025 |
CANF |
6-K filed: Foreign issuer report |
Filing |
— |
| November 10, 2025 |
PVLA |
Quarterly results filed (8-K) |
Earnings |
— |
| November 10, 2025 |
TARA |
Quarterly results filed (8-K) |
Earnings |
— |
| November 10, 2025 |
GKOS |
8-K filed: Reg FD disclosure |
Filing |
— |
| November 10, 2025 |
NKTR |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| November 10, 2025 |
MGTX |
8-K filed: Material agreement, Reg FD disclosure |
Corporate |
— |
| November 10, 2025 |
COGT |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| November 10, 2025 |
BLTE |
6-K filed: Foreign issuer report |
Filing |
— |
| November 10, 2025 |
OLMA |
Quarterly results filed (8-K) |
Earnings |
— |
| November 10, 2025 |
OCS |
6-K filed: Foreign issuer report |
Filing |
— |
| November 10, 2025 |
AVBP |
Quarterly results filed (8-K) |
Earnings |
— |
| November 10, 2025 |
QURE |
Quarterly results filed (8-K) |
Earnings |
— |
| November 10, 2025 |
NRIX |
8-K filed: Leadership change |
Corporate |
— |
| November 10, 2025 |
LYEL |
8-K filed: Material agreement, Reg FD disclosure |
Corporate |
— |
| November 10, 2025 |
EWTX |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| November 10, 2025 |
CAPR |
Quarterly results filed (8-K) |
Earnings |
— |
| November 10, 2025 |
BCAX |
Quarterly results filed (8-K) |
Earnings |
— |
| November 10, 2025 |
LRMR |
8-K filed: Other event |
Filing |
— |
| November 10, 2025 |
KYNB |
Quarterly results filed (8-K) |
Earnings |
— |
| November 10, 2025 |
PROK |
Quarterly results filed (8-K) |
Earnings |
— |
| November 10, 2025 |
BFRI |
8-K filed: Other event |
Filing |
— |
| November 10, 2025 |
CRSP |
Quarterly results filed (8-K) |
Earnings |
— |
| November 10, 2025 |
CATX |
Quarterly results filed (8-K) |
Earnings |
— |
| November 10, 2025 |
NTHI |
8-K filed: Reg FD disclosure |
Filing |
— |
| November 10, 2025 |
MLYS |
Quarterly results filed (8-K) |
Earnings |
— |
| November 10, 2025 |
KYMR |
Safety, PK, PD, and Clinical Activity of Orally Administered KT-621 in Adult Patients With Atopic Dermatitis (AD) |
Trial Milestone |
Phase 1 |
| November 10, 2025 |
OGN |
Quarterly results filed (8-K) |
Earnings |
— |
| November 10, 2025 |
WVE |
Quarterly results filed (8-K) |
Earnings |
— |
| November 10, 2025 |
LXRX |
8-K filed: Other event |
Filing |
— |
| November 10, 2025 |
SPRB |
Quarterly results filed (8-K) |
Earnings |
— |
| November 10, 2025 |
MNKD |
ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension |
Trial Milestone |
Phase 3 |
| November 10, 2025 |
MNKD |
8-K filed: Other event |
Filing |
— |
| November 10, 2025 |
EDIT |
Quarterly results filed (8-K) |
Earnings |
— |
| November 10, 2025 |
AKBA |
Quarterly results filed (8-K) |
Earnings |
— |
| November 10, 2025 |
AGEN |
Quarterly results filed (8-K) |
Earnings |
— |
| November 10, 2025 |
NKTX |
Quarterly results filed (8-K) |
Earnings |
— |
| November 11, 2025 |
ALKS |
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2 |
Trial Milestone |
Phase 2 |
| November 12, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| November 12, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| November 12, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| November 12, 2025 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| November 12, 2025 |
BNTX |
6-K filed: Foreign issuer report |
Filing |
— |
| November 12, 2025 |
NBIX |
Extension Study to Evaluate How Safe and Tolerable NBI-921352 is as an Adjunctive Therapy for Participants With SCN8A-DEE |
Trial Milestone |
Phase 2 |
| November 12, 2025 |
INBS |
Quarterly results filed (8-K) |
Earnings |
— |
| November 12, 2025 |
ALKS |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| November 12, 2025 |
PRAX |
A Clinical Trial of PRAX-562 in Subjects With Developmental and Epileptic Encephalopathies (DEE) |
Trial Milestone |
Phase 2/Phase 3 |
| November 12, 2025 |
ZBIO |
Quarterly results filed (8-K) |
Earnings |
— |
| November 12, 2025 |
QNRX |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| November 12, 2025 |
ASND |
6-K filed: Foreign issuer report |
Filing |
— |
| November 12, 2025 |
ASND |
6-K filed: Foreign issuer report |
Filing |
— |
| November 12, 2025 |
ASND |
6-K filed: Foreign issuer report |
Filing |
— |
| November 12, 2025 |
LNTH |
8-K filed: Leadership change |
Corporate |
— |
| November 12, 2025 |
HUMA |
Quarterly results filed (8-K) |
Earnings |
— |
| November 12, 2025 |
LBRX |
8-K filed: Other event |
Filing |
— |
| November 12, 2025 |
TENX |
Quarterly results filed (8-K) |
Earnings |
— |
| November 12, 2025 |
IRD |
Quarterly results filed (8-K) |
Earnings |
— |
| November 12, 2025 |
VOR |
8-K filed: Other event |
Filing |
— |
| November 12, 2025 |
AVIR |
Quarterly results filed (8-K) |
Earnings |
— |
| November 12, 2025 |
PHVS |
6-K filed: Foreign issuer report |
Filing |
— |
| November 12, 2025 |
CRBP |
Quarterly results filed (8-K) |
Earnings |
— |
| November 12, 2025 |
LYEL |
Quarterly results filed (8-K) |
Earnings |
— |
| November 12, 2025 |
IMTX |
6-K filed: Foreign issuer report |
Filing |
— |
| November 12, 2025 |
SLS |
Quarterly results filed (8-K) |
Earnings |
— |
| November 12, 2025 |
IMRX |
Quarterly results filed (8-K) |
Earnings |
— |
| November 12, 2025 |
KYTX |
Quarterly results filed (8-K) |
Earnings |
— |
| November 12, 2025 |
NGNE |
8-K filed: Reg FD disclosure |
Filing |
— |
| November 12, 2025 |
ANRO |
Quarterly results filed (8-K) |
Earnings |
— |
| November 12, 2025 |
ABEO |
Quarterly results filed (8-K) |
Earnings |
— |
| November 12, 2025 |
ONCY |
6-K filed: Foreign issuer report |
Filing |
— |
| November 12, 2025 |
TTRX |
8-K filed: Reg FD disclosure |
Filing |
— |
| November 12, 2025 |
NTHI |
8-K filed: Reg FD disclosure |
Filing |
— |
| November 12, 2025 |
HALO |
8-K filed: Material agreement |
Corporate |
— |
| November 12, 2025 |
RADX |
6-K filed: Foreign issuer report |
Filing |
— |
| November 12, 2025 |
DMAC |
Quarterly results filed (8-K) |
Earnings |
— |
| November 12, 2025 |
COYA |
Quarterly results filed (8-K) |
Earnings |
— |
| November 12, 2025 |
CRMD |
Quarterly results filed (8-K) |
Earnings |
— |
| November 12, 2025 |
ERAS |
Quarterly results filed (8-K) |
Earnings |
— |
| November 12, 2025 |
BYSI |
Quarterly results filed (8-K) |
Earnings |
— |
| November 12, 2025 |
ATXI |
8-K filed: Material agreement, Leadership change, Other event |
Corporate |
— |
| November 12, 2025 |
TCRX |
Quarterly results filed (8-K) |
Earnings |
— |
| November 12, 2025 |
MBRX |
8-K filed: Reg FD disclosure |
Filing |
— |
| November 12, 2025 |
CELZ |
8-K filed: Leadership change |
Corporate |
— |
| November 12, 2025 |
ILMN |
8-K filed: Other event |
Filing |
— |
| November 13, 2025 |
PFE |
8-K filed: Other event |
Filing |
— |
| November 13, 2025 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| November 13, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| November 13, 2025 |
MRNA |
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults |
Trial Milestone |
Phase 2 |
| November 13, 2025 |
ZBIO |
A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease |
Trial Milestone |
Phase 3 |
| November 13, 2025 |
KOD |
Quarterly results filed (8-K) |
Earnings |
— |
| November 13, 2025 |
KLRA |
A Single-dose Study to Investigate the Effect of Injection Site on KAI-9531 Relative Bioavailability in a Range of Body Mass Indices |
Trial Milestone |
Phase 1 |
| November 13, 2025 |
CADL |
Quarterly results filed (8-K) |
Earnings |
— |
| November 13, 2025 |
ANVS |
Quarterly results filed (8-K) |
Earnings |
— |
| November 13, 2025 |
VTGN |
Quarterly results filed (8-K) |
Earnings |
— |
| November 13, 2025 |
CMPS |
Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD |
Trial Milestone |
Phase 3 |
| November 13, 2025 |
IMUX |
Quarterly results filed (8-K) |
Earnings |
— |
| November 13, 2025 |
MGTX |
Quarterly results filed (8-K) |
Earnings |
— |
| November 13, 2025 |
LBRX |
8-K filed: Material agreement |
Corporate |
— |
| November 13, 2025 |
RNAC |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| November 13, 2025 |
TRVI |
Quarterly results filed (8-K) |
Earnings |
— |
| November 13, 2025 |
COGT |
8-K filed: Material agreement, Other event |
Corporate |
— |
| November 13, 2025 |
GRCE |
Quarterly results filed (8-K) |
Earnings |
— |
| November 13, 2025 |
IMNN |
Quarterly results filed (8-K) |
Earnings |
— |
| November 13, 2025 |
ALMS |
Quarterly results filed (8-K) |
Earnings |
— |
| November 13, 2025 |
RLMD |
Quarterly results filed (8-K) |
Earnings |
— |
| November 13, 2025 |
TLSA |
6-K filed: Foreign issuer report |
Filing |
— |
| November 13, 2025 |
ORIC |
8-K filed: Reg FD disclosure |
Filing |
— |
| November 13, 2025 |
ORIC |
Quarterly results filed (8-K) |
Earnings |
— |
| November 13, 2025 |
ELDN |
8-K filed: Material agreement |
Corporate |
— |
| November 13, 2025 |
KURA |
8-K filed: Other event |
Filing |
— |
| November 13, 2025 |
AURA |
Quarterly results filed (8-K) |
Earnings |
— |
| November 13, 2025 |
CLRB |
Quarterly results filed (8-K) |
Earnings |
— |
| November 13, 2025 |
NGNE |
Quarterly results filed (8-K) |
Earnings |
— |
| November 13, 2025 |
TRAW |
Quarterly results filed (8-K) |
Earnings |
— |
| November 13, 2025 |
BFRI |
Quarterly results filed (8-K) |
Earnings |
— |
| November 13, 2025 |
OMER |
Quarterly results filed (8-K) |
Earnings |
— |
| November 13, 2025 |
RNXT |
Quarterly results filed (8-K) |
Earnings |
— |
| November 13, 2025 |
TTRX |
Quarterly results filed (8-K) |
Earnings |
— |
| November 13, 2025 |
SGMT |
Quarterly results filed (8-K) |
Earnings |
— |
| November 13, 2025 |
ALDX |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| November 13, 2025 |
RVPH |
Quarterly results filed (8-K) |
Earnings |
— |
| November 13, 2025 |
OTLK |
8-K filed: Other event |
Filing |
— |
| November 13, 2025 |
CRDL |
6-K filed: Foreign issuer report |
Filing |
— |
| November 13, 2025 |
CRDL |
6-K filed: Foreign issuer report |
Filing |
— |
| November 13, 2025 |
MBRX |
8-K filed: Reg FD disclosure |
Filing |
— |
| November 13, 2025 |
FATE |
Quarterly results filed (8-K) |
Earnings |
— |
| November 13, 2025 |
ACRV |
Quarterly results filed (8-K) |
Earnings |
— |
| November 13, 2025 |
PGEN |
Quarterly results filed (8-K) |
Earnings |
— |
| November 13, 2025 |
LTRN |
Quarterly results filed (8-K) |
Earnings |
— |
| November 13, 2025 |
QTTB |
Quarterly results filed (8-K) |
Earnings |
— |
| November 14, 2025 |
AZN |
6-K filed: Corporate announcement |
Corporate |
— |
| November 14, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| November 14, 2025 |
SNY |
Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS) |
Trial Milestone |
Phase 3 |
| November 14, 2025 |
SNY |
Study on Immunogenicity and Safety of a Meningococcal ACYW Conjugate Vaccine in Healthy Infants and Toddlers |
Trial Milestone |
Phase 3 |
| November 14, 2025 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| November 14, 2025 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| November 14, 2025 |
CYTK |
8-K filed: Leadership change |
Corporate |
— |
| November 14, 2025 |
VRCA |
Quarterly results filed (8-K) |
Earnings |
— |
| November 14, 2025 |
ANNX |
8-K filed: Material agreement, Other event |
Corporate |
— |
| November 14, 2025 |
CGON |
8-K filed: Leadership change |
Corporate |
— |
| November 14, 2025 |
CGON |
Quarterly results filed (8-K) |
Earnings |
— |
| November 14, 2025 |
IKT |
Quarterly results filed (8-K) |
Earnings |
— |
| November 14, 2025 |
AWHL |
Quarterly results filed (8-K) |
Earnings |
— |
| November 14, 2025 |
SRRK |
8-K filed: Other event |
Filing |
— |
| November 14, 2025 |
SRRK |
Quarterly results filed (8-K) |
Earnings |
— |
| November 14, 2025 |
ELDN |
Quarterly results filed (8-K) |
Earnings |
— |
| November 14, 2025 |
MCUJF |
6-K filed: Foreign issuer report |
Filing |
— |
| November 14, 2025 |
RNXT |
8-K filed: Material agreement |
Corporate |
— |
| November 14, 2025 |
NTHI |
Quarterly results filed (8-K) |
Earnings |
— |
| November 14, 2025 |
BCLI |
Quarterly results filed (8-K) |
Earnings |
— |
| November 14, 2025 |
ENSC |
Quarterly results filed (8-K) |
Earnings |
— |
| November 14, 2025 |
HURA |
Quarterly results filed (8-K) |
Earnings |
— |
| November 14, 2025 |
FTH |
Quarterly results filed (8-K) |
Earnings |
— |
| November 15, 2025 |
SNY |
Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa |
Trial Milestone |
Phase 3 |
| November 15, 2025 |
LNTH |
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer |
Trial Milestone |
Phase 1/Phase 2 |
| November 17, 2025 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| November 17, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| November 17, 2025 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| November 17, 2025 |
IONS |
8-K filed: Material agreement, Other event |
Corporate |
— |
| November 17, 2025 |
JAZZ |
8-K filed: Other event |
Filing |
— |
| November 17, 2025 |
MRNA |
Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of Age |
Trial Milestone |
Phase 3 |
| November 17, 2025 |
MIRM |
8-K filed: Other event |
Filing |
— |
| November 17, 2025 |
NUVB |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| November 17, 2025 |
FDMT |
8-K filed: Leadership change |
Corporate |
— |
| November 17, 2025 |
QNRX |
8-K filed: Leadership change |
Corporate |
— |
| November 17, 2025 |
VSTM |
8-K filed: Other event |
Filing |
— |
| November 17, 2025 |
MESO |
6-K filed: Foreign issuer report |
Filing |
— |
| November 17, 2025 |
IMTX |
6-K filed: Foreign issuer report |
Filing |
— |
| November 17, 2025 |
ORMP |
Quarterly results filed (8-K) |
Earnings |
— |
| November 17, 2025 |
ORMP |
8-K filed: Material agreement |
Corporate |
— |
| November 17, 2025 |
RADX |
6-K filed: Foreign issuer report |
Filing |
— |
| November 17, 2025 |
BLRX |
6-K filed: Foreign issuer report |
Filing |
— |
| November 17, 2025 |
WVE |
8-K filed: Reg FD disclosure |
Filing |
— |
| November 17, 2025 |
ENSC |
8-K filed: Material agreement, Other event |
Corporate |
— |
| November 17, 2025 |
AKBA |
8-K filed: Material agreement |
Corporate |
— |
| November 17, 2025 |
CNSY |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| November 17, 2025 |
DRUG |
6-K filed: Foreign issuer report |
Filing |
— |
| November 17, 2025 |
DRUG |
6-K/A filed: Foreign issuer report |
Filing |
— |
| November 18, 2025 |
BMY |
8-K filed: Other event |
Filing |
— |
| November 18, 2025 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| November 18, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| November 18, 2025 |
SNY |
6-K filed: Foreign issuer report |
Filing |
— |
| November 18, 2025 |
ARGX |
6-K filed: Foreign issuer report |
Filing |
— |
| November 18, 2025 |
ARWR |
8-K filed: Other event |
Filing |
— |
| November 18, 2025 |
INSM |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| November 18, 2025 |
CANF |
6-K filed: Foreign issuer report |
Filing |
— |
| November 18, 2025 |
COGT |
8-K filed: Material agreement |
Corporate |
— |
| November 18, 2025 |
OLMA |
8-K filed: Other event |
Filing |
— |
| November 18, 2025 |
RADX |
6-K filed: Foreign issuer report |
Filing |
— |
| November 18, 2025 |
OKYO |
6-K filed: Foreign issuer report |
Filing |
— |
| November 18, 2025 |
LPCN |
8-K filed: Other event |
Filing |
— |
| November 18, 2025 |
LPCN |
8-K filed: Other event |
Filing |
— |
| November 18, 2025 |
ATXI |
8-K filed: Other event |
Filing |
— |
| November 18, 2025 |
HURA |
8-K filed: Other event |
Filing |
— |
| November 18, 2025 |
ALZN |
8-K filed: Other event |
Filing |
— |
| November 18, 2025 |
APLM |
6-K filed: Foreign issuer report |
Filing |
— |
| November 18, 2025 |
GNPX |
8-K filed: Other event |
Filing |
— |
| November 19, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| November 19, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| November 19, 2025 |
ABBV |
A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease |
Trial Milestone |
Phase 2 |
| November 19, 2025 |
NVO |
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor |
Trial Milestone |
Phase 3 |
| November 19, 2025 |
GILD |
8-K filed: Leadership change |
Corporate |
— |
| November 19, 2025 |
ONC |
8-K filed: Material agreement |
Corporate |
— |
| November 19, 2025 |
AAPG |
6-K filed: Foreign issuer report |
Filing |
— |
| November 19, 2025 |
ALKS |
8-K filed: Material agreement, Reg FD disclosure |
Corporate |
— |
| November 19, 2025 |
EYPT |
8-K filed: Other event |
Filing |
— |
| November 19, 2025 |
BSX |
8-K filed: Leadership change |
Corporate |
— |
| November 19, 2025 |
TARA |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| November 19, 2025 |
OLMA |
8-K filed: Other event |
Filing |
— |
| November 19, 2025 |
IVVD |
8-K filed: Material agreement, Other event |
Corporate |
— |
| November 19, 2025 |
ONCY |
6-K filed: Foreign issuer report |
Filing |
— |
| November 19, 2025 |
MCUJF |
6-K filed: Foreign issuer report |
Filing |
— |
| November 19, 2025 |
MCUJF |
6-K filed: Foreign issuer report |
Filing |
— |
| November 19, 2025 |
NERV |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| November 19, 2025 |
RADX |
6-K filed: Foreign issuer report |
Filing |
— |
| November 19, 2025 |
TPST |
8-K filed: Material agreement, Leadership change, Other event |
Corporate |
— |
| November 19, 2025 |
CLLS |
6-K filed: Foreign issuer report |
Filing |
— |
| November 19, 2025 |
APLM |
6-K filed: Foreign issuer report |
Filing |
— |
| November 19, 2025 |
GNPX |
8-K filed: Other event |
Filing |
— |
| November 20, 2025 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| November 20, 2025 |
NVS |
6-K filed: Foreign issuer report |
Filing |
— |
| November 20, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| November 20, 2025 |
AMGN |
A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque Psoriasis |
Trial Milestone |
Phase 3 |
| November 20, 2025 |
SVA |
6-K filed: Foreign issuer report |
Filing |
— |
| November 20, 2025 |
MRNA |
8-K filed: Reg FD disclosure |
Filing |
— |
| November 20, 2025 |
CANF |
6-K filed: Foreign issuer report |
Filing |
— |
| November 20, 2025 |
MDWD |
6-K filed: Foreign issuer report |
Filing |
— |
| November 20, 2025 |
IKT |
8-K filed: Other event |
Filing |
— |
| November 20, 2025 |
DCTH |
8-K filed: Other event |
Filing |
— |
| November 20, 2025 |
EWTX |
8-K filed: Leadership change |
Corporate |
— |
| November 20, 2025 |
MAIA |
8-K filed: Other event |
Filing |
— |
| November 20, 2025 |
ONCY |
6-K filed: Foreign issuer report |
Filing |
— |
| November 20, 2025 |
VALN |
6-K filed: Foreign issuer report |
Filing |
— |
| November 20, 2025 |
RADX |
6-K filed: Foreign issuer report |
Filing |
— |
| November 21, 2025 |
LLY |
A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN) |
Trial Milestone |
Phase 3 |
| November 21, 2025 |
LLY |
8-K filed: Leadership change |
Corporate |
— |
| November 21, 2025 |
PFE |
A Study to Learn How the Study Medicine Called Ibuzatrelvir is Taken up Into the Blood in Healthy Chinese Adults |
Trial Milestone |
Phase 1 |
| November 21, 2025 |
PFE |
8-K filed: Other event |
Filing |
— |
| November 21, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| November 21, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| November 21, 2025 |
AMGN |
A Trial to Assess the Effect of Kidney Impairment on How AMG 133 is Absorbed, Broken Down, and Eliminated by the Body |
Trial Milestone |
Phase 1 |
| November 21, 2025 |
INSM |
Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex |
Trial Milestone |
Phase 3 |
| November 21, 2025 |
IMVT |
8-K filed: Leadership change |
Corporate |
— |
| November 21, 2025 |
CANF |
6-K filed: Foreign issuer report |
Filing |
— |
| November 21, 2025 |
PVLA |
A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations |
Trial Milestone |
Phase 2 |
| November 21, 2025 |
NKTR |
8-K filed: Leadership change |
Corporate |
— |
| November 21, 2025 |
IKT |
8-K filed: Material agreement, Other event |
Corporate |
— |
| November 21, 2025 |
TNGX |
8-K filed: Material agreement |
Corporate |
— |
| November 21, 2025 |
MAIA |
8-K filed: Other event |
Filing |
— |
| November 21, 2025 |
OKYO |
6-K filed: Foreign issuer report |
Filing |
— |
| November 21, 2025 |
BYSI |
8-K filed: Material agreement |
Corporate |
— |
| November 21, 2025 |
MBRX |
8-K filed: Listing / standard notice |
Corporate |
— |
| November 21, 2025 |
ACTU |
8-K filed: Other event |
Filing |
— |
| November 21, 2025 |
GNPX |
8-K filed: Other event |
Filing |
— |
| November 22, 2025 |
AMGN |
A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Teprotumumab (AMG 632) Administered Intravenously in Healthy Chinese Participants |
Trial Milestone |
Phase 1 |
| November 24, 2025 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| November 24, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| November 24, 2025 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| November 24, 2025 |
NBIX |
8-K filed: Leadership change |
Corporate |
— |
| November 24, 2025 |
MRNA |
8-K filed: Material agreement |
Corporate |
— |
| November 24, 2025 |
VRCA |
8-K filed: Material agreement, Other event |
Corporate |
— |
| November 24, 2025 |
IVVD |
8-K filed: Other event |
Filing |
— |
| November 24, 2025 |
MESO |
6-K filed: Foreign issuer report |
Filing |
— |
| November 24, 2025 |
HALO |
8-K filed: Leadership change |
Corporate |
— |
| November 24, 2025 |
BLRX |
6-K filed: Foreign issuer report |
Filing |
— |
| November 24, 2025 |
MBRX |
8-K filed: Reg FD disclosure |
Filing |
— |
| November 25, 2025 |
NVS |
6-K filed: Foreign issuer report |
Filing |
— |
| November 25, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| November 25, 2025 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| November 25, 2025 |
AAPG |
6-K filed: Foreign issuer report |
Filing |
— |
| November 25, 2025 |
ARWR |
Quarterly results filed (8-K) |
Earnings |
— |
| November 25, 2025 |
MESO |
6-K filed: Foreign issuer report |
Filing |
— |
| November 25, 2025 |
TLSA |
6-K filed: Foreign issuer report |
Filing |
— |
| November 25, 2025 |
ALT |
IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH) |
Trial Milestone |
Phase 2 |
| November 25, 2025 |
RADX |
6-K filed: Foreign issuer report |
Filing |
— |
| November 25, 2025 |
HURA |
8-K filed: Reg FD disclosure |
Filing |
— |
| November 25, 2025 |
ILMN |
8-K filed: Other event |
Filing |
— |
| November 26, 2025 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| November 26, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| November 26, 2025 |
BNTX |
6-K filed: Foreign issuer report |
Filing |
— |
| November 26, 2025 |
NUVB |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| November 26, 2025 |
ASND |
6-K filed: Foreign issuer report |
Filing |
— |
| November 26, 2025 |
NKTR |
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA) |
Trial Milestone |
Phase 2 |
| November 26, 2025 |
CGON |
8-K filed: Leadership change |
Corporate |
— |
| November 26, 2025 |
ATNM |
8-K filed: Leadership change |
Corporate |
— |
| November 26, 2025 |
MESO |
6-K filed: Foreign issuer report |
Filing |
— |
| November 26, 2025 |
VERA |
8-K filed: Leadership change |
Corporate |
— |
| November 26, 2025 |
RXRX |
8-K filed: Other event |
Filing |
— |
| November 26, 2025 |
VALN |
6-K filed: Foreign issuer report |
Filing |
— |
| November 26, 2025 |
LKFT |
6-K filed: Foreign issuer report |
Filing |
— |
| November 26, 2025 |
TPST |
8-K filed: Other event |
Filing |
— |
| November 26, 2025 |
TCRX |
8-K filed: Leadership change |
Corporate |
— |
| November 26, 2025 |
GNPX |
8-K filed: Listing / standard notice |
Corporate |
— |
| November 28, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| November 28, 2025 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| November 28, 2025 |
TAK |
6-K filed: Foreign issuer report |
Filing |
— |
| November 28, 2025 |
VNDA |
8-K filed: Other event |
Filing |
— |
| November 28, 2025 |
AAPG |
6-K filed: Foreign issuer report |
Filing |
— |
| November 28, 2025 |
IMCR |
8-K filed: Leadership change |
Corporate |
— |
| November 28, 2025 |
TRAW |
8-K filed: Leadership change |
Corporate |
— |
| November 28, 2025 |
VALN |
6-K filed: Foreign issuer report |
Filing |
— |
| November 28, 2025 |
MBRX |
8-K filed: Other event |
Filing |
— |
| November 28, 2025 |
ACTU |
8-K filed: Material agreement |
Corporate |
— |
| November 30, 2025 |
SVA |
Efficacy, Safety, and Immunogenicity of the Bivalent Inactivated Enterovirus Vaccine (Vero Cell) |
Trial Milestone |
Phase 3 |